Sensor Pharmaceuticals Inc. is using its Synitivity technology to modify and restrict small molecules to the gut, thereby preventing systemic absorption and reducing potential toxicity. The company expects the improved safety will allow it to combine multiple gut-restricted compounds into single therapeutic agents that have additive or synergistic effects in diabetes, obesity or inflammatory bowel disease.

The company is pursuing targets whose signaling regulates the systemic production of multiple pro-inflammatory cytokines, such as G protein-coupled receptor 119 (GPR119), GPR120 and toll-like receptor 4 (TLR4).